Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Screenshot of an interview with Terry Keys
October 16th 2024

Combatting Misconceptions of Clinical Trials to Improve Patient Participation

Laura Joszt, MA
There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Screenshot of an interview with Naoto Ueno, MD, PhD
October 15th 2024

Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage

Alexandra Gerlach Laura Joszt, MA
Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.
Medicinal cannabis | image: NJ.gov
October 14th 2024

Navigating the Complexities of Cancer Care: Cannabis and Cost Considerations

Laura Joszt, MA
Doing Things Differently: Wilfong Moves to Thyme Care
October 12th 2024

Doing Things Differently: Wilfong Moves to Thyme Care

Mary Caffrey
Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, is senior vice president, value-based care, Thyme Care.
Oncology models | Image credit: Navista
October 11th 2024

Tangle of Tech: How Community Oncology Practices Can Successfully Navigate the Health Technology Landscape

Nini Wu, MD, MBA Anish Arora
Patient Navigation | Image credit: CDC
October 11th 2024

Setting the Course for Comprehensive Care Navigation in Oncology

Vishnukamal Golla, MD, MPH Allan Zuckoff, PhD Lucy MacPhail, PhD John Tam, MD Chevon Rariy, MD
AJMC
October 11th 2024

Racial and Ethnic Disparities in Prior Authorizations for Patients With Cancer

Benjamin Ukert, PhD Stephanie Schauder, PhD Daniel Cullen, PhD David Debono, MD Michael Eleff, MD Michael J. Fisch, MD, MPH
The prior authorization process for patients with cancer demonstrates fewer days until submission and lower denial rates for Asian patients relative to White patients.
Corey McEwen, PharmD, MS
October 10th 2024

Defining Value in Oncology Pharmacy: Insights on Care and Costs

Maggie L. Shaw
The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the oncology space.
Hands holding green lymphoma ribbon | Image credit: sulit.photos - stock.adobe.com
October 9th 2024

Childhood Lymphoma: Raising Awareness for Early Detection and Better Outcomes

Pearl Steinzor
It is important to educate and bring awareness to childhood lymphoma, its symptoms, treatment options, and the need for support.
Cancer screening | Image credit: kenchiro168 - stock.adobe.com
October 3rd 2024

Fear of Recurrence Is Common Among Adult Survivors of Childhood Cancer

Pearl Steinzor
Adults who survived childhood cancer experience elevated fear that their primary cancer will recur or that a subsequent malignant neoplasm will develop, according to a new study.
Managing AEs of Cannabis Use in Patients With Cancer
September 29th 2024

Managing AEs of Cannabis Use in Patients With Cancer

Laura Joszt, MA
There are some short-lived, common adverse events for patients using cannabis, but also some more dangerous, less common ones in chronic users, explained Marie Parish, PharmD, BCOP, of Mayo Clinic.
dr linda bosserman
September 27th 2024

Expanding Access to Innovative Cancer Treatments

Brooke McCormick
Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, discusses the implementation of cutting-edge cancer treatments, emphasizing the need for effective information sharing and collaboration to improve cancer care access for diverse populations.
dr andrew leitner
September 26th 2024

Increasing Access to Supportive Oncology Care Can Drive Health Equity

Brooke McCormick
Andrew Leitner, MD, of City of Hope, discusses the challenges of integrating supportive care into cancer treatment and proposes solutions to improve access for patients from underserved communities.
Closing Gaps in Value-Based Cancer Care
September 25th 2024

Closing Gaps in Value-Based Cancer Care

Brooke McCormick
Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, emphasizes the need for a sustainable health care system that balances cost with care so patients can achieve the best survival and quality of life after a cancer diagnosis.
Ted Okon, MBA
September 24th 2024

New FTC Lawsuit Against PBMs Has Broad Implications for Pharmaceuticals, Ted Okon Says

Julia Bonavitacola Skylar Jeremias
Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit managers (PBMs) could affect the future of pharmaceuticals and oncology.
dr andrew leitner
September 24th 2024

Spotlighting the Critical Role of Supportive Care in Cancer Treatment

Brooke McCormick
Andrew Leitner, MD, City of Hope, highlights the essential role of supportive care in improving the quality of life of patients with cancer undergoing treatment.
Chemotharapy graphic-tashatuvango-stock.adobe.com.jpeg
September 23rd 2024

Higher Risk of Heart Events in Older Cancer Survivors Linked to Chemotherapy

Pearl Steinzor
New research highlights increased stroke, heart attack, and heart failure risks in cancer survivors, especially those treated with chemotherapy.
Glenn Balasky during a video interview
September 22nd 2024

AI in Cancer Care Can Be Powerful, but There Will Be Learning Curves, Says Glenn Balasky

Alexandra Gerlach Laura Joszt, MA
Demonstration projects to show accurate use of artificial intelligence (AI) in cancer care are important to prevent a loss of credibility in the technology, explained Glenn Balasky, executive director, Rocky Mountain Cancer Centers.
dr joseph alvarnas
September 22nd 2024

Precision, Personalization, and Equity: Key Trends Shaping the Future of Cancer Care

Brooke McCormick
Joseph Alvarnas, MD, of City of Hope, discusses how he envisions the future of cancer care over the next decade.
dr joseph alvarnas
September 20th 2024

IVBM Chair Summarizes Key Takeaways on Value-Based Oncology Care

Brooke McCormick
Joseph Alvarnas, MD, of City of Hope, recaps yesterday's Institute for Value-Based Medicine® (IVBM) event on value-based oncology care, emphasizing patient-centered approaches and how attendees can apply these insights in their daily practice.
AJMC
September 20th 2024

Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs

Deborah R. Kaye, MD, MS Hui-Jie Lee, PhD Alexander Gordee, MA Daniel J. George, MD Charles D. Scales Jr, MD, MSHS Peter A. Ubel, MD M. Kate Bundorf, PhD, MBA, MPH
The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.
Incorporating Discussions of Cannabis Use Into Oncology Care Visits
September 15th 2024

Incorporating Discussions of Cannabis Use Into Oncology Care Visits

Laura Joszt, MA
The legalization of recreational marijuana in Minnesota has created daily conversations about how to incorporate the use of cannabis into treatment plans for patients with cancer, explained Marie Parish, PharmD, BCOP, of Mayo Clinic.
Cancer health care concept-wladimir1804-stock.adobe.com
September 13th 2024

From Policy to Practice: NCCN Summit Explores Equity in the Cancer Workforce

Giuliana Grossi
The National Comprehensive Cancer Network Policy Summit emphasized the importance of integrating diversity, equity, and inclusion into the oncology workforce to improve cancer care outcomes and address disparities while navigating legal and societal challenges.
Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer
September 13th 2024

Addressing Disparities in Long-Term Survivorship and Quality of Life for Young Patients With Breast Cancer

Alana Hippensteele
Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.
Dax Kurbegov, MD, senior vice president, Sarah Cannon Cancer Network
September 12th 2024

Dr Dax Kurbegov on Gaps Between Payers, Health Systems, and Providers in Oncology

Rose McNulty
Dax Kurbegov, MD, senior vice president of Sarah Cannon Cancer Network, discussed divides between payers, health systems, and oncology care providers, as well as the impacts these divides can have on patients.
Brain MRI | Image credit: stockdevil - stock.adobe.com
September 11th 2024

TIM3 Targeted Immunotherapy Shows Promise in Pediatric Brain Cancer

Pearl Steinzor
Breakthrough research identifies TIM3 as a key target in MAPK-activated pediatric gliomas, offering new hope for more effective immunotherapy treatments.
AJMC
September 6th 2024

The Feasibility and Equity of Text Messaging to Determine Patient Eligibility for Lung Cancer Screening

Ilona Fridman, PhD Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C Christine M. Neslund-Dudas, PhD Jennifer Elston Lafata, PhD
Text messaging shows promise for assessing smoking status and identifying lung cancer screening eligibility, particularly among middle-aged, educated individuals with medium or high income. However, a multimodal approach is crucial for equitable implementation of such a program.
Doctor and patient with breast cancer. | Image Credit: Pixel-Shot - stock.adobe.com .jpeg
September 3rd 2024

The Connection Between Cancer Treatment Choices and Suicide Mortality

Pearl Steinzor
Patients with cancer who forego surgery have higher suicide incidence than those who undergo treatment, a study finds.
When to Pause Before Recommending Cannabis to Patients With Cancer
September 1st 2024

When to Pause Before Recommending Cannabis to Patients With Cancer

Laura Joszt, MA
Despite lacking some data, there is some information on which patients with cancer shouldn’t be recommended cannabis or certain cannabis products, said Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic.
Matthew Nielsen, MD
August 31st 2024

Using Active Surveillance to Spare Men From Unneeded Prostate Cancer Treatment

Laura Joszt, MA
Advances in technology have made active surveillance in men with prostate cancer possible and prevented treatment for men who don’t need it, said Matthew Nielsen, MD, FACS, chair, Department of Urology, University of North Carolina School of Medicine.
<12345678910
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo